Abstract 328P
Background
Breast cancer (BC) is the most common malignancy in female patients (pts) with Li-Fraumeni Syndrome (LFS). These pts are at increased risk of other malignancies, including radiotherapy-induced malignancies (RIM) that are those occurring in a previously irradiated field. We aimed to evaluate the frequency of RIM and other oncologic outcomes of LFS pts with eBC.
Methods
We evaluated pts with a germline pathogenic/likely pathogenic variant of TP53 (LFS) diagnosed with eBC and followed by the Hereditary Cancer Team of a single cancer center between Dec/99 and Apr/23. The primary endpoint was the frequency of RIM among pts treated with adjuvant RT.
Results
Forty-nine pts were evaluated. Median age was 39 years (range 21 - 62); 79% were ER-positive; 35% HER2-positive; 35% stage I and 27% stage II; and 71% had TP53 R337H variant. Most pts (87%) were unaware of the LFS at the time of BC treatment. Regarding treatment, 62% underwent a mastectomy, 66% (neo)adjuvant chemotherapy, and 62% RT. The use of RT was more common after conservative surgery as expected (87% vs 46% with mastectomy, P=0.010). Oncologic outcomes are summarized in the table. Among 30 pts treated with RT, 4 (13.8%) developed RIM in the irradiated field (3 soft tissue malignancies and 1 BC). The occurrence of RIM was not influenced by RT dose (≤ 40.8 or > 40.8), but was influenced by the type of RT. RIM was observed in 100% with 2D RT (n=2/2), 100% (n=1/1) with volumetric modulated arc therapy (VMAT), 6% (n=1/16) with 3D RT, and 0% with intensity-modulated RT (n=0/1) (P=0.007). Table: 328P
Radiotherapy (n=30) | No radiotherapy (n=18) | P | |
Local recurrence | 2 (6.7%) | 1 (5.6%) | 1.000 |
Distant recurrence | 5 (16.7%) | 1 (5.6%) | 0.388 |
Contralateral BC | 5 (16.7%) | 2 (11.1%) | 0.696 |
Second neoplasia | 15 (50%) | 5 (27.8%) | 0.226 |
RIM | 4 (13.8%) | - | - |
Conclusions
Our study confirms an alarming rate of RIM after adjuvant RT, highlighting the need for a careful risk-benefit evaluation for the indication of RT, which should be preferentially avoided if possible. Despite the small numbers in each subgroup, the risk of RIM seemed to be influenced by the RT technique, with higher rates with 2D RT and VMAT. Early TP53 testing is crucial to guide the BC treatment plan.
Clinical trial identification
Editorial acknowledgement
Legal entity responsible for the study
The authors.
Funding
Has not received any funding.
Disclosure
V. Petry: Financial Interests, Personal, Advisory Board: AstraZeneca, Daiichi Sankyo, Novartis. R. Colombo Bonadio: Financial Interests, Personal, Invited Speaker: AstraZeneca, Daiichi Sankyo, Gilead, Nestle Health, Zodiac; Financial Interests, Personal, Expert Testimony: Ache; Financial Interests, Institutional, Research Funding: Novartis, AstraZeneca. L. Testa: Financial Interests, Personal, Advisory Board: AstraZeneca, Lilly, Novartis, Daiichi Sankyo, MSD; Financial Interests, Institutional, Research Funding: Novartis; Financial Interests, Personal, Invited Speaker: AstraZeneca, Roche, Daiichi Sankyo, MSD, Lilly, Zodiac, Pfizer. All other authors have declared no conflicts of interest.
Resources from the same session
323P - Macrophage population analysis of the breast cancer microenvironment within the context of seroma formation after mastectomy (SerMa pilot study)
Presenter: Felicitas Schneider
Session: Poster session 02
325P - Impact of breast tumour location on axillary nodal involvement, chemotherapy use, and survival
Presenter: Yang Xu
Session: Poster session 02
326P - Sentinel lymph node mapping in breast cancer: Evaluating the dual-tracer method with indocyanine green and radioisotope
Presenter: Ava Kwong
Session: Poster session 02
329P - Pulmonary function and lung fibrosis up to 12 years after breast cancer radiotherapy
Presenter: Jarle Karlsen
Session: Poster session 02
330P - Effect of radiotherapy in deep inspiration in patients with left breast cancer: Does the size of the target area affect the dose for the most crucial organs at risk?
Presenter: Zoltan Locsei
Session: Poster session 02
331P - miR-21 and miR-34a as biomarkers of radiotherapy skin adverse events in ductal carcinoma in situ
Presenter: Tanja Marinko
Session: Poster session 02
332P - Early prediction of residual cancer burden to neoadjuvant chemotherapy in breast cancer by longitudinal MRI-based multitask learning: A multicenter cohort study
Presenter: Wei Li
Session: Poster session 02
333P - Evaluation of a composite PET/CT and HER2 tissue-based biomarker to predict response to neoadjuvant HER2-directed therapy in early breast cancer (TBCRC026)
Presenter: Maeve Hennessy
Session: Poster session 02